Phase 2aData readout

JOTROL (Resveratrol)

Parkinson's disease

JUNSJupiter Neurosciences

Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset: JOTROL (Resveratrol)
Development stage: Phase 2a
Event type: Data readout
Indication: Parkinson's disease

Research summary

What is being tracked?

This catalyst tracks a Phase 2a data readout for JOTROL (Resveratrol) in Parkinson's disease. The expected timing is based on the latest available company guidance and may change.

Development notes

11/5/25– FDA clears IND. Enrollment to start in early 2026. 05/27/26:- Ph2a RESET (NCT07592767) enrolling; study completion projected H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source